Medidata, a subsidiary of Dassault Systèmes, and Project ALS have entered a research partnership in order to develop new therapeutic strategies for the treatment of Amyotrophic lateral sclerosis (ALS).

Also known as Lou Gehrig’s disease, ALS is a neurodegenerative disease closely related to Alzheimer’s, Parkinson’s, and Huntington’s diseases.

Under the partnership, Medidata will apply its artificial intelligence tools to aid the fight against ALS.

The research efforts will use Medidata’s Rave Omics, a biomarker discovery solution and part of company’s Acorn AI portfolio, which streamlines omic (including genomic, proteomic, and transcriptomic) data capture within the clinical study process.

Acorn AI was developed to focus on speeding up the development of analytics and AI solutions in clinical development.

Medidata co-founder and co-CEO Glen de Vries said: “We are proud to partner with Project ALS on such an important quest. The patients and the researchers inspire us, they are the basis of our mission to use technology to change lives.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We look forward to applying Medidata’s next-generation tools to deepen our understanding of this devastating disease, and accelerate the pace of new discoveries.”

The agreement with Project ALS expands on the Medidata Institute’s programmes to advance precision medicine.

The new initiative is part of Medidata’s ongoing commitment to rare diseases.

Project ALS research advisory board member Neil Shneider said: “ALS is a complex, heterogeneous disease, and treatment of its various forms may require specific therapies targeting distinct ALS subtypes.

“I’m eager to begin working with Medidata’s Acorn AI team to define these subtypes, and to develop a precision medicine approach to our treatment of ALS.”

Medidata claims to have supported biopharma companies in conducting over 1,200 rare disease studies involving more than 190,000 patients.

The company’s Cloud-based platform allows clinical trials to run smoother, faster, and safer for patients.